Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,600 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 November 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 216 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 26 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is W  [Clear All Filters]
2020
C. Santella, Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., and Azoulay, L., “Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes”, Epidemiology, 2020.
H. Strongman, Williams, R., and Bhaskaran, K., “What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? a concordance and validation study using linked English electronic health records data”, BMJ Open, vol. 10, p. e037719, 2020.
J. S. Minhas, Coles, B., Mistri, A. K., Eveson, D. J., Hussain, S. T., Potter, J. F., Khunti, K., and Robinson, T. G., “What is the optimal blood pressure level for patients with atrial fibrillation treated with direct oral anticoagulants?”, J Hypertens, 2020.
W. D. Strain, Tsang, C., Hurst, M., McEwan, P., Unadkat, M., Meadowcroft, S., Shardlow, R., and Evans, M., “What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient”, Diabetes Ther, vol. 11, pp. 1381-1395, 2020.
2019
A. M. Mueller, Meier, C. R., Jick, S. S., and Schneider, C., “Weight change and blood glucose concentration as markers for pancreatic cancer in subjects with new-onset diabetes mellitus: A matched case-control study”, Pancreatology, 2019.
C. Broadhurst, Rhodes, A. M. L., Harper, P., Perry, D. C., Clarke, N. M. P., and Aarvold, A., “What is the incidence of late detection of developmental dysplasia of the hip in England?”, Bone Joint J, vol. 101-b, pp. 281-287, 2019.
A. P. McGovern, Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., and Jones, A. G., “What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study”, BMC Med, vol. 17, p. 79, 2019.
P. A. Tiffin, Mediavilla, J. L., Close, H., Kasim, A. S., Welsh, P., Paton, L. W., and Mason, J. M., “What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study”, BMJ Open, vol. 9, p. e028201, 2019.
C. Gilbert, Allgar, V., and Doran, T., “Workload impact of the Quality and Outcomes Framework for patients with diabetes: an interrupted time series in general practice”, Br J Gen Pract, vol. 69, pp. e570-e577, 2019.
2018
V. M. Walker, Davies, N. M., Kehoe, P. G., and Martin, R. M., “What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink”, Alzheimers Res Ther, vol. 10, p. 51, 2018.
2017
T. P. Chu, Shah, A., Walker, D., and Coleman, M. P., “Where are the opportunities for an earlier diagnosis of primary intracranial tumours in children and young adults?”, Eur J Paediatr Neurol, vol. 21, pp. 388-395, 2017.
2016
B. T. Blak, Rigney, U., Sternhufvud, C., Davis, J., and Hammar, N., “Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class”, Int J Clin Pract, vol. 70, pp. 45-55, 2016.
A. J. Walker, West, J., Card, T. R., Crooks, C., Kirwan, C. C., and Grainge, M. J., “When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data”, Blood, vol. 127, pp. 849-57; quiz 953, 2016.
J. C. Robson, Kiran, A., Maskell, J., Hutchings, A., Arden, N., Dasgupta, B., Hamilton, W., Emin, A., Culliford, D., and Luqmani, R., “Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study”, J Rheumatol, vol. 43, pp. 1085-92, 2016.
2015
N. M. Davies, Taylor, G., Taylor, A. E., Thomas, K. H., Windmeijer, F., Martin, R. M., and Munafo, M. R., “What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study”, BMJ Open, vol. 5, p. e009665, 2015.
S. Mukherjee, Culliford, D., Arden, N., and Edwards, C., “What is the risk of having a total hip or knee replacement for patients with lupus?”, Lupus, vol. 24, pp. 198-202, 2015.
2014
E. Kontopantelis, Springate, D., Reeves, D., Ashcroft, D. M., Valderas, J. M., and Doran, T., “Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework”, Bmj, vol. 348, p. g330, 2014.
2012
C. L. Morgan, Jenkins-Jones, S., Evans, M., Barnett, A. H., Poole, C. D., and Currie, C. J., “Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs”, Diabetes Obes Metab, vol. 14, pp. 424-32, 2012.
C. L. Morgan, Poole, C. D., Evans, M., Barnett, A. H., Jenkins-Jones, S., and Currie, C. J., “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes”, J Clin Endocrinol Metab, vol. 97, pp. 4605-12, 2012.
2011
L. Watson, Wilson, B. P., Alsop, J., and Kumar, S., “Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?”, Diabetes Obes Metab, vol. 13, pp. 823-31, 2011.
2009
D. Kernick, Stapley, S., Campbell, J., and Hamilton, W., “What happens to new-onset headache in children that present to primary care? A case-cohort study using electronic primary care records”, Cephalalgia, vol. 29, pp. 1311-6, 2009.
2008
T. P. van Staa, Smeeth, L., Persson, I., Parkinson, J., and Leufkens, H. G., “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
2004
G. E. Smith, Smith, S., Heatlie, H., Bashford, J. N., Hawker, J., Ashcroft, D., Millson, D., Verlander, N. Q., and Warren, R., “What has happened to antimicrobial usage in primary care in the United Kingdom since the SMAC report? - description of trends in antimicrobial usage using the General Practice Research Database”, J Public Health (Oxf), vol. 26, pp. 359-64, 2004.
M. Ashworth, Latinovic, R., Charlton, J., Cox, K., Rowlands, G., and Gulliford, M., “Why has antibiotic prescribing for respiratory illness declined in primary care? A longitudinal study using the General Practice Research Database”, J Public Health (Oxf), vol. 26, pp. 268-74, 2004.
2003
C. C. Yang, Jick, S. S., and Testa, M. A., “Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation”, Br J Clin Pharmacol, vol. 55, pp. 288-98, 2003.
1998
J. N. Bashford, Norwood, J., and Chapman, S. R., “Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database”, Bmj, vol. 317, pp. 452-6, 1998.
[Page last reviewed 6 November 2020]